Monte Rosa Therapeutics announced an underwritten public offering of 11,125,000 shares of common stock at $24.00 per share and 1,375,000 pre-funded warrants at $23.9999 each, before exercise price, expected to generate approximately $300 million in gross proceeds. The company also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares at the same public offering price, less underwriting discounts and commissions. All securities in the offering are being sold by Monte Rosa, with the offering set to close on or about January 12, 2026, subject to customary closing conditions.

Proceeds from the offering will bolster Monte Rosa’s balance sheet as it advances three clinical-stage molecular glue degrader (MGD) programs across oncology, autoimmune and inflammatory indications. The additional capital is earmarked for expansion of the QuEEN™ discovery engine, which integrates AI-guided chemistry, structural biology and proteomics, and to fund ongoing collaborations with pharmaceutical partners in immunology, oncology and neurology. Management has indicated that the financing will support IND filings for two new MGD candidates by late 2026.

Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers, while Wedbush PacGrow and LifeSci Capital serve as passive bookrunners. The offering is being conducted off an effective shelf registration statement (SEC File No. 333-285942), declared effective March 31, 2025. Final prospectus supplements will be available through the syndicate managers and via the SEC’s EDGAR system, and the company expects to complete the transaction in mid-January pending regulatory clearance.

Monte Rosa has established the industry’s leading pipeline of first-in-class and only-in-class MGDs, leveraging its proprietary QuEEN™ platform to achieve high selectivity for target neosubstrates. With three programs in clinical development and multiple partnerships, the financing positions the company to sustain its early-mover advantage in the $15 billion targeted protein degrader market, where competitors have yet to match the breadth of Monte Rosa’s degrader portfolio.